To our knowledge, no trial has specifically studied the effect of liraglutide combined with a
basal/bolus insulin regimen in type 1 diabetes in a cross-over, double-blind, unicentric
model. Moreover, the potential impact of a glucagon-like peptide-1 agonist on measures of
abdominal fat (assessed by CT scan), insulin sensitivity (assessed by the gold standard
euglycemic-hyperinsulinemic clamp) and satiety sensations have not been evaluated in this
population.
Hypothesis Overweight participants with type 1 diabetes on liraglutide/insulin treatment will
present improved glucose control with decreased HbA1c, decreased fasting and mean weekly
glucose concentrations and glycemic excursions as well as increased insulin sensitivity
compared to participants on placebo/insulin treatment. Participants with liraglutide/insulin
treatment will also present improved endothelial function, lower body weight, central adipose
tissue assessed by CT scan and higher satiety sensations assessed by visual analogue scales.
Phase:
Phase 4
Details
Lead Sponsor:
Centre Hospitalier Universitaire de Québec, CHU de Québec CHU de Quebec-Universite Laval